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Abstract 
Background: Prescription opioid drug overdose mortality rates have surpassed those of motor 
vehicle accidents in Kentucky. While opioid overdose plagues the state, buprenorphine is an 
FDA approved medication that has proven effective in treating opioid dependence. Objectives: 
This study examined the supply of licensed buprenorphine providers and community treatment 
centers in each county of Kentucky along with the need for treating opioid use disorder in each 
county.  Methods: Licensed buprenorphine physicians and community treatment centers 
prescribing buprenorphine were identified through the Substance Abuse and Mental Health 
Services Administration online treatment locator. The need for treatment was measured by 
calculating the crude opioid overdose hospitalization rates in each county, year 2008 through 
2012. Results: Results of this study conclude Eastern Kentucky has the greatest need for opioid 
treatment along with a small pocket of Northern Kentucky. Forty six percent of Kentucky 
counties (n=56) have at least one licensed buprenorphine physician and eight counties house 
community treatment centers prescribing buprenophine. Discussion: The need for treatment is 
greater than the current supply of physicians and treatment centers. Figures included in this study 
illustrate clearly where current treatment providers are located and where need is most prevalent. 
Conclusion: Future policy must address gaps in treatment supply and treatment needs to identify 
treatment solutions and curb opioid dependence. Buprenorphine is the gold-star standard in 
opioid dependence treatment and requires significantly less resources then other types of opioid 
treatment.  
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1. INTRODUCTION 
 Opioid dependence is a public health concern that is causing increased mortality rates 
across the nation. The Centers for Disease Control reports a hundred people die every day in the 
United States from drug overdoses and that drug overdose death rates have tripled since 2008.
1
 
Prescription painkillers, known as opioid pain relievers, are the culprit of three out of four drug 
overdoses in the United States.
1
 
 In 2002 the U.S. Food and Drug Administration (FDA) approved buprenorphine as a 
unique treatment option to combat opioid use disorder (OUD). Licensed buprenorhphine 
physicians have the ability to prescribe buprenorphine treatment outside of substance abuse 
clinical settings. Buprenorphine offers a viable treatment option for individuals unable or 
unwilling to seek care in traditional treatment settings.
2
 Opioid use disorder is a treatable disease: 
the National Institutes of Health Consensus Statement concluded in 1997, “All persons 
dependent on opiates should have access to opiate agonist treatment”.
3
,
4
Methadone is also an 
FDA approved OUD treatment option. Methadone treatment is restricted to hospitals along with 
federal and state approved opioid replacement substance abuse programs. Research studies 
examining OUD patient treatment preference indicate individuals suffering from OUD prefer 
buprenorphine over methadone because of the length of methadone treatment; methadone 
maintenance treatment is a long-term indefinite treatment regimen with rigorous structure.
5 
Longitudinal studies spanning three decades indicate the majority of patients receiving 
methadone treatment drop out within the first year and refer to methadone as a “substitute drug” 
because of treatment length and structure. 
5-8
Research found OUD patients perceive methadone 
as a “harmful drug” and buprenorphine as “helpful medicine”.
5
 Clinical research studies suggest 
buprenorphine has a better safety profile and lower abuse liability than methadone. 
6 
Based upon 
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previous research findings and patient attitudes buprenoprhine treatment supply is the focus of 
this study. 
 Opioid addiction medication has continuously proved effective; however, access to 
medication is a public health concern. Bodies of research cite similar factors affecting the 
availability of buprenorphine treatment. The primary barrier preventing individuals from 
receiving treatment is insurance coverage. As a result of low Medicaid reimbursement rates 
physicians typically accept only cash or private insurance for services rendered.
5, 9
 Opioid 
dependent populations struggle to maintain employment because of their addiction, which limits 
their ability to see physicians who only accept private insurance. The cost of office based opioid 
treatment (OBOT) in Kentucky averages $940/month.
10 
Individuals suffering with OUD 
commonly rely upon community treatment centers for care due to insufficient insurance 
coverage and high medication expenses.  
 The inequality of buprenorphine treatment extends beyond insured and uninsured 
individuals; it also exists among publicly funded treatment centers and private treatment 
providers.
11
Buprenorphine is an evidence-based program and considered the gold standard in 
opioid agonist therapy but research has continuously found the use of buprenorphine more 
prevalent in accredited, for-profit facilities.
11-14 
A contributing factor in the difference of 
buprenorphine usage among publicly funded treatment centers and private provider treatment 
revolves around the adoption of evidence-based programs. Publicly funded community based 
treatment programs face barriers when adopting evidence-based programs because of financial 
factors and limited connections with research institutions.
9,13,15-18  
The majority of community 
center patients do not have private insurance, therefore community centers do not have the funds 
to be able to employ licensed buprenorphine physicians. Without licensed buprenorphine 
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physicians, community centers are not able to prescribe buprenorphine to patients in need. A 
limited amount of publicly funded buprenorphine treatment centers threatens the supply of 
feasible treatment options for vulnerable OUD users and creates a market for street 
buprenorphine and buprenoprhine diversion.   
 Previous studies examining Kentucky buprenorphine diversion suggest diversion may be 
a direct result of limited access to treatment and an in increase to access may be an effective 
response in curbing diversion.
10
 The most frequent barrier preventing physicians from obtaining 
licensure is physician attitudes; physicians express concern about the  lack of financial 
reimbursement for behavioral health and substance abuse services.
6,19
 Requirements for 
physicians to become buprenrophine licensed consist of verifying physicians are certified 
addiction specialists, have participated as principal investigators in clinical trials with 
buprenorphine for the treatment of opioid dependence, or received eight hours of approved 
training on the appropriate use of buprenorphine for the treatment of opioid dependence. 
20 
Most 
physicians become licensed through the eight hour training. An estimated twenty-three thousand 
physicians out of eight hundred thousand physicians in the United States (2.9%) have the 
necessary credentials to prescribe buprenorphine.
21 Physicians are not permitted to treat more 
than thirty patients concurrently during their first year of prescribing. After one year physicians 
can choose to increase their patient load to one hundred patients.  
 
As Kentucky and the United States struggle with growing opioid mortality rates it is 
beneficial to understand the supply of buprenorphine treatment providers and centers compared 
to treatment demand among the OUD population. National ratios suggest that for every one 
prescription pain-pill death there are ten treatment admissions for abuse, thirty-two emergency 
department visits for misuse or abuse and one-hundred thirty people who are drug 
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dependent.
1
The objective of this study is to examine if the supply of buprenorphine treatment 
providers and centers in Kentucky meets the need for treatment need. Previous research has 
identified barriers preventing buprenorphine treatment expansion, but to our knowledge, no 
study in Kentucky has examined the current supply and need for buprenorphine treatment 
options in Kentucky. This study will recognize service gaps that may exist across the state and 
encourage policy recommendations to increase accessible buprenorphine treatment options for 
Kentucky’s suffering OUD population.  
2. METHODS 
Variables  
 The dependent variable of this study is the number of buprenorphine treatment providers 
in each county. The independent variable of this study is the crude county rates of drug overdose 
hospitalizations per 10,000 populations. The purpose of this study is to determine whether a 
relationship exists between the variables and whether the supply of buprenorphine providers is 
meeting the need for OUD treatment.  
Measures 
 The purpose of this study is to examine the supply of buprenorpohine treatment in 
relation to need for treatment. Supply of buprenorphine treatment was measured by totaling the 
number of physicians and treatment center programs available in all one hundred and twenty 
Kentucky counties. To illustrate the supply of buprenorphine treatment, physicians and treatment 
centers were mapped according to the geographic location of the facility. Physicians located at 
the same address located within the same practice were counted individually. Need for 
buprenorphine treatment was measured according to the individual county crude opioid overdose 
hospitalization rates per 10,000 population for the years 2008 through 2012. Hospitalization rates 
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were calculated according to the geographic location of a patient’s address, not the address of the 
facility visited. Need calculations only included Kentucky residents treated in Kentucky acute 
care hospitals.  
Data Collection  
 Licensed buprenorphine physicians were identified through the online buprenorphine 
treatment program locator funded by the Center for Substance Abuse Treatment (CSAT) and 
Substance Abuse Mental Health Services Administration (SAMHSA), which also provides the 
address and location of each licensed physician.
22
 We acknowledge the CSAT provider treatment 
data is not an entirely inclusive list of providers; however this is the most accessible public 
information that patients and families of patients suffering from OUD have access to. It would be 
difficult to identify every buprenorphine treatment provider and facility as we recognize 
physicians may become licensed while we complete this study and others may cease practice. As 
of December 2013, CSAT identified three hundred and three physicians and twenty-three 
treatment center programs offering services in Kentucky. Physician and treatment center 
program data used for the purpose of this study includes physicians that are authorized to 
prescribe buprenorphine along with treatment programs that are authorized to dispense 
buprenorphine. Buprenorphine prescribing physicians in this study have met qualifications under 
the Drug Addiction Treatment Act of 2000 (DATA 2000) and authorized the use of their names 
to appear in the buprenorphine treatment locator.  
 The present study utilizes a statewide report produced by the Kentucky Injury Prevention 
Research Center (KIPRC), which counted the number of opioid overdose hospitalizations from 
years 2008 through 2012. The KIPRC report presents drug overdose morbidity and mortality 
data for Kentucky residents. KIPRIC used multiple data sources to report hospitalization rates; 
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including Kentucky Inpatient Hospitalization Discharge Files from the Cabinet for Health and 
Family Services, Office of Health Policy, 2000-2012. A hospitalization was considered a drug 
overdose if any of the ICD-9-CM codes in the range of 960-979 were listed in any diagnoses 
(principal or secondary) fields.
19
 Overdose hospitalizations of years 2008 through 2012 were 
combined and stratified by Kentucky county (n=120). Combining individual counties’ five year 
opioid overdose hospitalization counts produced large enough counts to support statistically 
significant analyses. The Kentucky data management policy requires suppression of counts less 
than five; no counties in Kentucky had less than five observations. Five year hospitalization 
counts were calculated into crude county rates of drug overdose hospitalizations per 10,000 
populations. Data used in this study is statistically significant; however, Kentucky residents 
receiving treatment in neighboring states are not considered in this study. Opioid overdose 
hospitalizations measure the need for buprenorphine treatment. Individuals who have been 
hospitalized as a result of opioid overdose represent a population that has the opportunity to be 
served through treatment though we realize hospitalizations underestimate demand as not every 
OUD user ends up in the hospital. 
3. RESULTS 
Opioid Hospitalizations 
 Every county in Kentucky saw hospitalizations as a result of opioid overdose. The lowest 
crude rate of opioid hospitalizations between 2008 and 2012 was 5 hospitalizations per 10,000 
people. The counties with the greatest crude opioid overdose hospitalizations between 2008 and 
2012 in Kentucky were Owsley County (41/10,000ppl), Perry County (35/10,000ppl), and Wolfe 
County (32/10,000ppl). Counties with the fewest hospitalizations per ten-thousand people were 
Meade County (5/10,000ppl) followed by Spencer and Robertson Counties both with 6 
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hospitalizations per 10,000 individuals.  The mean crude rate of opioid hospitalizations per 
10,000 people in Kentucky years 2008 through 2012 was 15 per 10,000 population and the total 
number of hospitalizations statewide between 2008 and 2012 was over twenty-nine thousand 
(29,413).  Figure 1.0 illustrates regionally Eastern Kentucky and a pocket of Northern Kentucky 
experienced the most hospitalizations as a result of opioid overdose. Owsley, Perry, and Wolfe 
counties experienced more than double the statewide average of hospitalizations per 10,000 
people. Kentucky’s largest counties, Jefferson County (Louisville) and Fayette County 
(Lexington) both experienced a crude hospitalization rate of 12 individuals per 10,000, which is 
less than the state average. 
 Total opioid overdose hospitalization counts were most frequent in Jefferson, Fayette, 
Boone and Kenton counties for years 2008 through 2012. Each county experienced more than 
nine-hundred hospitalizations over the five years. Counties with the fewest number of 
hospitalizations were Robertson, Hickman, Menifee, and Elliott counties where there were less 
than fifty hospitalizations in the combined five years.  Calculating rates per 10,000 populations 
removes the variance of population among counties, however; hospitalization frequencies 
represent the actual number of cases in each county. Understanding the frequency of 
hospitalizations is important to calculate the ratio of patients per provider considering physicians 
are licensed to only treat up to one hundred patients.  
 Increased hospitalizations result in increased medical spending for taxpayers. According 
to a 2012 report funded by the U.S. Department of Health and Human Services, over twelve 
thousand individuals received some type of substance abuse treatment through Medicaid, 
whether it was inpatient or outpatient.
23
 In an eight county region of the Northern Kentucky 
pocket (Boone, Campbell, Carroll, Gallatin, Grant, Kenton, Owen and Pendleton Counties), 
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sixty-five percent of patients treated in hospitals for opioid addiction were self-pay (that is, 
uninsured).
24
A vast majority of self-pay patients are not able to pay for their medical services 
because of the effects addiction has had on their income and relationships with families. 
Hospitals and taxpayers are left to absorb the costs of patients with unpaid hospital bills.    
Buprenorphine Provider Trends 
 The state of Kentucky has one hundred-twenty counties, forty six percent (n=56) 
of Kentucky counties have at least one licensed buprenorphine physician and fifty four percent 
(n=64) do not have a licensed buprenorphine physician within their county. The number of 
licensed buprenorphine practitioners as of December 2013 was three-hundred and three and the 
number of treatment centers prescribing buprenorphine was twenty-three. Fayette County has the 
greatest number of licensed buprenorphine providers with sixty-one. Jefferson County is the 
largest county in Kentucky and has the second most licensed buprenrphine providers with fifty-
three. The vast majority of buprenorphine treatment is available in Central Kentucky.  
Buprenorphine physicians are able to treat thirty patients during their first year of 
licensure and up to one hundred patients total after their first year of licensure. A problem that 
counties without licensed physicians or only a few licensed physicians face is that there is a 
greater need for treatment then providers are able to provide. An extreme example of this is in 
Campbell County, where there were seven hundred and seventy three hospitalizations occurred, 
but there is only one licensed physician within the county. It is not possible for one physician to 
treat the number of Campbell County opioid overdose hospitalizations. Twenty seven counties 
have rates of patients per physician over one hundred.  
Regionally, Eastern Kentucky is where the greatest need for treatment lies despite 
providers being located in these areas. The population of Wolfe County is less than eight 
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thousand people and five licensed buprenorphine physicians are located in the county along with 
a community treatment program, yet Wolfe County still experiences the third highest opioid 
hospitalization rates per ten-thousand people. Perry County has a population of roughly twenty-
eight thousand people and the county is equipped with five licensed providers along with two 
community treatment centers but still deals with the second largest opioid overdose 
hospitalizations per ten-thousand people. Future studies should seek to understand why these 
areas are experiencing the highest rate of hospitalizations if providers are available.  
Furthermore, consider Owsley County with a crude hospitalization rate of forty-one people per 
ten thousand. The population of Owsley County is just over fourteen thousand meaning at a 
minimum, forty-one individuals were hospitalized; Owsley County has one licensed physician. 
The supply of physicians is not evenly dispersed among the state to meet the needs of each 
county. The twenty-three community treatment centers able to prescribe buprenorphine are 
spread among sixteen counties. Access to community treatment programs requires travelling a 
significant distance for the majority of Kentucky’s suffering OUD population.  
 Research suggests that nationwide buprenorphine licensure is on the rise despite 
physician hesitation due to medication costs and lack of financial reimbursement. The number of 
buprenorphine providers has increased in Kentucky, and may continue to do so if an ethical 
financial reimbursement system is established that presents neither a financial incentive nor a 
financial hardship for physicians deciding to pursue buprenorphine licensure. As opioid 
addiction continues to be rampant in the state of Kentucky it may be useful that the number of 
buprenorphine licensed physicians increase, especially around counties and regions lacking 
sufficient access; however, new clinics and physicians should be managed and monitored closely 
to ensure ethical practices are operating and benefitting OUD patients. 
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4. DISCUSSION 
 Between years 2008 and 2012, hospitalization rates surpassed typical Kentucky averages. 
While it appears the number of licensed buprenorphine providers is increasing, findings of this 
study suggest areas of Kentucky with the highest rates of opioid hospitalizations do not have a 
sufficient supply of buprenorphine providers to make an impact towards reducing opioid 
hospitalizations. Eastern Kentucky suffers with the greatest number of hospitalizations; two of 
the three counties with the highest hospitalization rate per ten-thousand people border one 
another, and the third county is located within fifty miles. Moreover, findings in this study reveal 
a lack of community treatment centers. Prior research suggests OUD users most commonly seek 
treatment from community treatment centers. A lack of community treatment centers in Eastern 
Kentucky may factor into the high opioid hospitalizations in this region along with greatly 
impacting the overall supply of accessible treatment options throughout the state. The majority of 
Kentucky’s community treatment programs able to prescribe buprenorphine are located in larger, 
more populous counties. Future considerations should include building community treatment 
center capacities in regions where opioid overdose hospitalizations per ten-thousand populations 
are the highest. Increasing access to community treatment programs will minimize or remove 
barriers that currently prevent OUD users from seeking treatment. 
Limitations 
 There are limitations to the findings. This study only analyzed the supply of licensed 
buprenorphine physicians and community treatment centers currently prescribing buprenorphine. 
As we previously mentioned, buprenorphine is not the only effective treatment for opioid 
addiction. Other limitations include using the SAMHSA buprenorphine treatment locator to 
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count physicians. The SAMHSA treatment locator may underestimate the number of physicians 
as it only includes physicians who have authorized their name to be listed and does not provide 
information regarding whether physicians are able to treat thirty or one-hundred patients. The 
Drug Enforcement Administration - National Technical Information Service (DEA NTIS) data 
base provides buprenorphine physician data as well, but risks over estimates of licensed 
physicians as not all physicians who are licensed treat patients. A drawback of the DEA NTS 
data base is that it must be purchased and is costly. This study aimed to examine the supply of 
physicians through easily accessible public information that OUD users are more likely to use. 
This study explored the aggregate number of physicians as of December 2013, but did not 
examine the increase of buprenorphine licensure from year to year.  
 Other potential limitations include overestimates or underestimates of opioid 
hospitalizations. Patients may be misdiagnosed as suffering from opioid overdose or 
misdiagnosed as not suffering from opioid overdose. Hospitalization rates used in this study 
relied upon ICD-9-CM codes in the range of 960-979 listed in any diagnoses (principal or 
secondary) fields. Relying upon hospital billing ICD-9-CM codes contributes to the risk of 
miscoded diagnoses and/or skewed occurrences of a specific condition.  
 Future studies need to examine barriers preventing treatment expansion in areas of 
Kentucky currently experiencing the greatest opioid overdose hospitalization rates. Interventions 
need to be developed that encourage general practice physicians to become buprenorphine 
licensed and connect with OUD patients in their area. Encompassing substance abuse into 
regular discussions with general practice physicians at health check-ups would be a step towards 
removing the stigmatization of opioid addiction.  Opioid addiction carries a heavy stigmatization, 
often a stigma persuasive enough to deter users from seeking treatment for the fear of being 
 
Buprenorphine Treatment Supply and Need 
14 
 
labeled a drug addict. More education needs to be available to educate communities and the 
public about the illness of addiction. An educational focus should be centered on removing the 
stigma of treatment and educate about the success of treatment to foster healthy treatment 
options within communities Future policy must identify and establish an ethical structure 
promoting successful buprenorphine treatment and establishing a reliable financial 
reimbursement scale that is fair for both patient and provider. Research should continue to 
examine efficacious opioid addiction treatments that may be easily implemented in areas of high 
need.  
5. CONCLUSION 
 Understanding the supply and need for buprenorphine providers is necessary to shape 
future substance abuse treatment policy and legislation. Medication-assisted treatment, 
residential treatment, and detoxification have all simultaneously been scrutinized and merited 
successful. Each type of treatment affects individuals differently and there is not one “cure all” 
for opioid dependent populations, therefore adequate options must be available to solve the 
opioid epidemic. As opioid abuse continues to engulf the state of Kentucky, policy makers and 
public health officials must recognize that all types of treatment have the potential to be misused, 
abused, or land in the wrong hands; however, the goal of public health and medical officials 
should be to provide enough treatment service options and education to benefit the most people.  
It is unlikely that opioid overdose hospitalizations will decrease unless actions are taken to 
increase access to treatment.  
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  Hospitalizations     Absolute 
  per 10,000  Number of Number of 
Number of  
County  
County population Providers Treatment Centers Hospitalizations 
Owsley 42 1 0 99 
Perry 35 5 2 501 
Wolfe 32 3 1 116 
Breathitt 30 3 1 204 
Bell 29 1 0 412 
Clay 28 2 0 306 
Johnson 27 4 0 309 
Knott 27 2 1 214 
Knox 27 4 0 418 
Lee 27 1 1 105 
Casey 26 1 0 208 
Grant 24 1 0 295 
Madison 24 4 0 770 
Martin 24 0 0 158 
McCreary 23 0 0 145 
Whitley 23 3 1 409 
Floyd 22 9 0 416 
Gallatin 22 0 0 93 
Lawrence 22 3 0 169 
Livingston 22 0 0 101 
Daviess 21 4 0 991 
Kenton 20 5 0 1546 
Taylor 20 1 0 242 
Graves 19 1 0 348 
Fulton 18 0 0 60 
Grayson 18 0 0 223 
Harlan 18 2 0 260 
Leslie 18 1 1 101 
Letcher 18 1 1 213 
Bath 17 0 0 99 
Campbell 17 1 0 773 
Clinton 17 0 0 85 
McCracken 17 2 1 267 
Ohio 17 0 0 194 
Pendleton 17 0 0 124 
Pike 17 16 0 541 
Pulaski 17 3 0 507 
Boone 16 4 1 958 
Boyd 16 12 0 394 
Butler 16 0 0 97 
Carlisle 16 0 0 41 
Cumberland 16 0 0 55 
Powell 16 0 0 101 
Carroll 15 2 0 77 
Jessamine 15 2 0 345 
Marion 15 0 0 68 
Nicholas 15 0 0 50 
Allen 14 0 0 115 
Hopkins 14 1 0 329 
Rockcastle 14 2 0 118 
Russell 14 2 0 123 
Barren 13 0 0 259 
Boyle 13 16 0 174 
Bracken 13 0 0 55 
Carter 13 1 0 179 
Laurel 13 9 0 380 
Rowan 13 1 0 180 
Adair 12 5 0 112 
Ballard 12 0 0 50 
Table 1.0 Kentucky County Snapshots 
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Bourbon 12 2 0 120 
Caldwell 12 0 0 75 
Edmonson 12 0 0 70 
Estill 12 0 0 88 
Fayette 12 61 2 1728 
Fleming 12 0 0 80 
Franklin 12 7 0 280 
Garrard 12 0 0 96 
Green 12 0 2 65 
Jefferson 12 53 4 4370 
Lincoln 12 0 0 142 
Lyon 12 0 0 50 
Magoffin 12 0 0 106 
Owen 12 0 0 62 
Simpson 12 0 0 100 
Warren 12 7 0 666 
Anderson 11 1 0 110 
Breckenridge 11 0 0 110 
Calloway 11 0 0 190 
Clark 11 0 0 186 
Crittenden 11 0 0 50 
Hardin 11 8 2 549 
Menifee 11 0 0 34 
Elliott 10 0 0 36 
Greenup 10 1 0 177 
Hancock 10 0 0 39 
Hart 10 1 1 83 
Jackson 10 0 0 68 
Logan 10 0 0 135 
Mason 10 2 0 97 
McLean 10 0 0 83 
Mercer 10 3 0 105 
Montgomery 10 3 0 121 
Morgan 10 0 0 67 
Muhlenburg 10 1 0 149 
Scott 10 4 0 217 
Wayne 10 0 0 96 
Webster 10 0 0 63 
Bullitt 9 0 0 322 
Henderson 9 0 0 191 
Hickman 9 2 0 21 
Larue 9 0 0 62 
Metcalfe 9 0 1 41 
Monroe 9 0 0 46 
Woodford 9 0 0 105 
Henry 8 0 0 57 
Marshall 8 0 0 322 
Nelson 8 0 0 162 
Washington 8 0 0 42 
Harrison 7 0 0 59 
Todd 7 0 0 39 
Trigg 7 0 0 50 
Trimble 7 0 0 31 
Christian 6 5 0 215 
Lewis 6 0 0 42 
Oldham 6 1 0 181 
Robertson 6 0 0 6 
Shelby 6 0 0 115 
Spencer 6 0 0 44 
Union 6 0 0 43 
Meade 5 0 0 72 
Table 1.0- Counties are arranged from highest hospitalization rates to lowest , between the years of 2008 and 2012. The absolute number of 
county hospitalizations is the specific number of opioid overdose hospitalizations that occurred in each county during 2008 through 2012. 
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